8 Dermatology Headlines You Missed in November 2025

The month of November 2025 saw a wide array of notable events take place in the field of dermatology, and many of these headlines were covered by the HCPLive editorial team.

In November’s iteration of the Month in Review series, HCPLive has listed 8 significant headlines of note in the skin health space. The list includes news covered in November regarding treatments such as risankizumab and upadacitinib, as well as US Food and Drug Administration (FDA) news regarding roflumilast cream 0.3% for children with atopic dermatitis.

Additionally, this review highlights several notable interviews and other news released following 3 conferences: the Society of Dermatology Physician Associates (SDPA) Fall Conference in Texas, the American College of Allergy, Asthma, & Immunology (ACAAI) Annual Scientific Meeting in Florida, and the Fall Clinical Dermatology Conference in Nevada. The following list provides key updates on developments in dermatology:

Risankizumab Effective as Treatment for Psoriasis in Genital, Scalp Regions

In 1 story covered in November 2025, new data showed risankizumab could be an efficacious and safe therapy for patients with moderate-to-severe psoriasis in the genital and scalp regions. This conclusion was the result of phase 4 findings in an analysis authored by such investigators as Eingun James Song, MD, director of clinical research at Frontier Dermatology. Song et al’s UnlIMMited study found, in addition to the higher clearance rates observed with risankizumab versus placebo, no new safety signals for the drug, supporting its use in sensitive psoriasis regions.

OX40/OX40 Ligand Target Offers Broader Acting Therapy for Atopic Dermatitis, With Raj Chovatiya, MD, PhD

During the 2025 ACAAI Annual Scientific Meeting in Orlando, Florida, Raj Chovatiya, MD, PhD, of Northwestern University’s Feinberg School of Medicine, spoke with the HCPLive team about his talk, ‘7 for 11: Hot Therapeutic Targets in Allergy and Immunology.’ He highlighted takeaways from his session on OX40/OX40L, otherwise known as the interaction between the costimulatory TNF receptor OX40 and its ligand, OX40L, and its role in atopic conditions.

Treating Dermatology Patients with Off-Label JAK Inhibitors, With Gabriela Maloney, DO

During the SDPA Fall Conference in San Antonio, the HCPLive team spoke with Gabriela Maloney, DO, a board-certified dermatologist at Forefront Dermatology, about her conference session titled ‘Off-Label Usage of JAK Inhibitors.’ Ever since ruxolitinib cream’s FDA approval in 2021, making this topical treatment the first Janus kinase (JAK) inhibitor approved in dermatology, JAK inhibitors have seen expansions in their use. Maloney highlighted off-label JAK inhibitors’ use in a variety of conditions, pointing, for example, to bullous diseases such as bullous pemphigoid, pemphigus vulgaris, lichen planus erosive lichen planus, and cicatricial alopecia.

Guidelines Presented on Managing Genetic Skin Disorders and Referring Patients

Another story highlighted at the SDPA Fall Conference highlighted coverage of a session at the meeting titled ‘The ABCs of Genetic Disorders of the Skin: Guidelines for Recognition and When to Refer.’ Presented by Yasmine Kirkorian, MD, the chief of the Division of Pediatric Dermatology at Children’s National Hospital (CNH), this talk reviewed several commonly observed genetic syndromes with cutaneous manifestations. These included tuberous sclerosis, neurofibromatosis type 1, and others. During her session, Kirkorian emphasized the recognition of skin findings resulting in a referral to a geneticist or a specialty clinic.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD

In an interview conducted during the 2025 Fall Clinical Dermatology Conference, Peter A. Lio, MD, a clinical professor of Dermatology at the Icahn School of Medicine at Mount Sinai and clinical assistant professor of Dermatology & Pediatrics at Northwestern University’s Feinberg School of Medicine, spoke on several notable takeaways from his sessions at the meeting in Las Vegas. In this interview, Lio highlighted news on several treatments in the armamentarium, such as topical ruxolitinib, a JAK inhibitor, and its approval down to the age of 2 years. He also discussed topical tapinarof, an aryl hydrocarbon receptor agonist, and its recent age expansion.

FDA Accepts sNDA for Roflumilast Cream 0.3% in Children Ages 2 to 5 with Psoriasis

The FDA’s acceptance of a supplemental New Drug Application (sNDA) for roflumilast (Zoryve) cream 0.3% for children aged 2-5 years with psoriasis was also highlighted in November, potentially leading to an expansion in this drug’s indication. The drug was designed as a once-daily, advanced targeted topical phosphodiesterase-4 (PDE4) inhibitor. The November 17 announcement by Arcutis Biotherapeutics, Inc. highlighted a PDUFA target action date of June 29, 2026, for roflumilast cream’s approval for this new age range.

SCALE-UP: Findings on Real-World Use of Upadacitinib in Atopic Dermatitis

Other findings highlighted in November had been presented at the 2025 Fall Clinical Dermatology Conference, including new real-world data on upadacitinib’s use in atopic dermatitis. The findings, authored by such investigators as Jonathan Silverberg, MD, PhD, MPH, associate professor of Dermatology at The George Washington University School of Medicine and Health Sciences, resulted from the SCALE‐UP study. In their analysis, Silverberg et al pointed to upadacitinib’s significant clinical benefits in treating moderate-to-severe atopic dermatitis, highlighting the rapid reductions in itch and the rapid skin clearance seen in both AST-naïve and AST-experienced patients.

ARCADIA LTE: Long-term Nemolizumab Effective in Adolescents with Atopic Dermatitis

In other data covered at the Fall Clinical conference, treatment of adolescent patients with atopic dermatitis via nemolizumab 30 mg every 4 weeks (Q4W), along with a background of topical corticosteroids (TCS) of low/medium potency with/without topical calcineurin inhibitors (TCI), was shown to have improved key signs and symptoms. These findings resulted from a post hoc analysis from ARCADIA LTE and were authored by such investigators as Adam Reich, MD, PhD, a full-time professor at the Department of Dermatology, University of Rzeszów, Poland.